NCT07180082View on ClinicalTrials.gov

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions
Advanced Breast Cancer
Interventions
DRUG

Pyrotinib

anti-HER2 tyrosine kinase inhibitor

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjin Yin

OTHER